Interactions of miR-34b/c and TP-53 polymorphisms on the risk of nasopharyngeal carcinoma

Tumor Biology

Volumn 34, Issue 3, 2013, Pages 1919-1923

  Li, Lijuan ^a,b   Wu, Jian ^c   Sima, Xiutian ^d   Bai, Peng ^a   Deng, Wei ^a   Deng, Xueke ^b,e   Zhang, Lin ^a,b,e   Gao, Linbo ^b,e  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c CHONGQING UNIVERSITY CANCER HOSPITAL   (China)

^d SICHUAN UNIVERSITY   (China)

^e BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Genetic polymorphism; miR 34b c; Nasopharyngeal carcinoma; TP 53

Indexed keywords

ARGININE; MICRORNA; MICRORNA 34B; MICRORNA 34C; PROLINE; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE;

EID: 84878679747     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0736-9     Document Type: Article

References (42)

1. Bei JX, Li Y, Jia WH, Feng BJ, Zhou G, Chen LZ, et al. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet. 2010;42(7):599-603.
2. Chang CM, Yu KJ, Mbulaiteye SM, Hildesheim A, Bhatia K. The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal. Virus Res. 2009;143(2):209-21.
3. Cho WC. Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol Cancer. 2007;6:1.
4. Su CK, Wang CC. Prognostic value of Chinese race in nasopharyngeal cancer. Int J Radiat Oncol Biol Phys. 2002;54(3):752-8.
5. Rozan LM, El-Deiry WS. p53 downstream target genes and tumor suppression: a classical view in evolution. Cell Death Differ. 2007;14(1):3-9.
6. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253(5015):49-53.
7. Niedobitek G, Agathanggelou A, Barber P, Smallman LA, Jones EL, Young LS. P53 overexpression and Epstein-Barr virus infection in undifferentiated and squamous cell nasopharyngeal carcinomas. J Pathol. 1993;170(4):457-61.
8. Sheu LF, Chen A, Tseng HH, Leu FJ, Lin JK, Ho KC, et al. Assessment of p53 expression in nasopharyngeal carcinoma. Hum Pathol. 1995;26(4):380-6.
9. Ara S, Lee PS, Hansen MF, Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res. 1990;18(16):4961.
10. Hadhri-Guiga B, Toumi N, Khabir A, Sellami-Boudawara T, Ghorbel A, Daoud J, et al. Proline homozygosity in codon 72 of TP53 is a factor of susceptibility to nasopharyngeal carcinoma in Tunisia. Cancer Genet Cytogenet. 2007;178(2):89-93.
11. Jiang P, Liu J, Zeng X, Li W, Tang J. Association of TP53 codon 72 polymorphism with cervical cancer risk in Chinese women. Cancer Genet Cytogenet. 2010;197(2):174-8.
12. Gao LB, Li LJ, Pan XM, Li ZH, Liang WB, Bai P, et al. A genetic variant in the promoter region of miR-34b/c is associated with a reduced risk of colorectal cancer. Biol Chem. 2013;394(3):415-20.
13. Denisov EV, Cherdyntseva NV, Litvyakov NV, Slonimskaya EM, Malinovskaya EA, Voevoda MI, et al. TP53 mutations and Arg72Pro polymorphism in breast cancers. Cancer Genet Cytogenet. 2009;192(2):93-5.
14. Fernandez-Rubio A, Lopez-Cima MF, Gonzalez-Arriaga P, Garcia-Castro L, Pascual T, Marron MG, et al. The TP53 Arg72Pro polymorphism and lung cancer risk in a population of Northern Spain. Lung Cancer. 2008;61(3):309-16.
15. Chen HC, Chen GH, Chen YH, Liao WL, Liu CY, Chang KP, et al. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer. 2009;100(6):1002-11.
16. Luo Z, Zhang L, Li Z, Li X, Li G, Yu H, et al. An in silico analysis of dynamic changes in microRNA expression profiles in stepwise development of nasopharyngeal carcinoma. BMC Med Genomics. 2012;5:3.
17. Li T, Chen JX, Fu XP, Yang S, Zhang Z, Chen KH, et al. microRNA expression profiling of nasopharyngeal carcinoma. Oncol Rep. 2011;25(5):1353-63.
18. Xu Y, Liu L, Liu J, Zhang Y, Zhu J, Chen J, et al. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer. 2011;128(2):412-7.
19. Bossard P, Zaret KS. GATA transcription factors as potentiators of gut endoderm differentiation. Development. 1998;125(24):4909-17.
20. Chou J, Provot S, Werb Z. GATA3 in development and cancer differentiation: cells GATA have it! J Cell Physiol. 2010;222(1):42-9.
21. Li L, Sima X, Bai P, Zhang L, Sun H, Liang W, et al. Interactions of miR-34b/c and TP53 polymorphisms on the risk of intracranial aneurysm. Clin Dev Immunol. 2012;2012:567-86.
22. Calin GA, Sevignani C, Dan Dumitru C, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. P Natl Acad Sci USA. 2004;101(9):2999-3004.
23. Sevignani C, Calin GA, Nnadi SC, Shimizu M, Davuluri RV, Hyslop T, et al. MicroRNA genes are frequently located near mouse cancer susceptibility loci. Proc Natl Acad Sci U S A. 2007;104(19):8017-22.
24. Calin GA, Croce CM. Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications. J Clin Invest. 2007;117(8):2059-66.
25. Suzuki H, Toyota M, Sasaki Y, Maruyama R, Imai K, Shinomura Y, et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 2008;68(11):4123-32.
26. Lee CH, Subramanian S, Beck AH, Espinosa I, Senz J, Zhu SX, et al. MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS One. 2009;4(10):e7314.
27. He C, Xiong J, Xu X, Lu W, Liu L, Xiao D, et al. Functional elucidation of MiR-34 in osteosarcoma cells and primary tumor samples. Biochem Biophys Res Commun. 2009;388(1):35-40.
28. Lujambio A, Calin GA, Villanueva A, Ropero S, Sanchez-Cespedes M, Blanco D, et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA. 2008;105(36):13556-61.
29. Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, et al. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res. 2010;16(4):1119-28.
30. Kim NH, Kim HS, Kim NG, Lee I, Choi HS, Li XY, et al. p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signal. 2011;4(197):ra71.
31. Wei YG, Liu F, Li B, Chen X, Ma Y, Yan LN, et al. Interleukin-10 gene polymorphisms and hepatocellular carcinoma susceptibility: a meta-analysis. World J Gastroenterol. 2011;17(34):3941-7.
32. Zhang YM, Zhou XC, Xu Z, Tang CJ. Meta-analysis of epidemiological studies of association of two polymorphisms in the interleukin-10 gene promoter and colorectal cancer risk. Genet Mol Res. 2012;11(3):3389-97.
33. Tsai MH, Lin CD, Hsieh YY, Chang FC, Tsai FJ, Chen WC, et al. Prognostic significance of the proline form of p53 codon 72 polymorphism in nasopharyngeal carcinoma. Laryngoscope. 2002;112(1):116-9.
34. Tiwawech D, Srivatanakul P, Karaluk A, Ishida T. The p53 codon 72 polymorphism in Thai nasopharyngeal carcinoma. Cancer Lett. 2003;198(1):69-75.
35. Birgander R, Sjalander A, Zhou Z, Fan C, Beckman L, Beckman G. p53 polymorphisms and haplotypes in nasopharyngeal cancer. Hum Hered. 1996;46(1):49-54.
36. Yung WC, Ng MH, Sham JS, Choy DT. p53 codon 72 polymorphism in nasopharyngeal carcinoma. Cancer Genet Cytogenet. 1997;93(2):181-2.
37. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010;17(2):193-9.
38. Bale SJ, Dracopoli NC, Tucker MA, Clark Jr WH, Fraser MC, Stanger BZ, et al. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med. 1989;320(21):1367-72.
39. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle. 2008;7(16):2591-600.
40. Tanaka K, Yanoshita R, Konishi M, Oshimura M, Maeda Y, Mori T, et al. Suppression of tumourigenicity in human colon carcinoma cells by introduction of normal chromosome 1p36 region. Oncogene. 1993;8(8):2253-8.
41. Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazi D, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005;353(21):2243-53.
42. Cohen SM, Brennecke J, Stark A. Denoising feedback loops by thresholding - a new role for microRNAs. Genes Dev. 2006;20(20):2769-72.